Osiris Therapeutics Company Profile (NASDAQ:OSIR)

About Osiris Therapeutics

Osiris Therapeutics logoOsiris Therapeutics, Inc. is a medical products company. The Company is focused on developing and marketing products in regenerative medicine, including bioengineering, stem cell research and viable tissue based products. The Company's offers products in orthopedics, sports medicine and wound care, including Cartiform, BIO4 and Grafix. Cartiform is a viable chondral allograft containing viable chondrocytes, chondrogenic growth factors, and extracellular matrix proteins within the intact architecture of healthy hyaline cartilage. BIO4 is a bone allograft that contains both viable cells and growth factors. It is a safe alternative to autograft that minimizes the potential for harvest site co-morbidities. Grafix is a cryopreserved placental membrane that preserves the native properties and inherent functionality of the tissue.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: OSIR
  • CUSIP: 68827R10
Key Metrics:
  • Previous Close: $4.78
  • 50 Day Moving Average: $5.2017
  • 200 Day Moving Average: $5.2831
  • 52-Week Range: $34,452,000.00 - $3.55
  • Trailing P/E Ratio: 110.9548
  • Foreward P/E Ratio: 66.71
  • P/E Growth: 0.0000
  • Market Cap: $160.55M
  • Outstanding Shares: 34,452,000
  • Beta: 0.53
Additional Links:
Companies Related to Osiris Therapeutics:

Analyst Ratings

Consensus Ratings for Osiris Therapeutics (NASDAQ:OSIR) (?)
Ratings Breakdown: 1 Sell Rating, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $16.00 (242.61% upside)

Analysts' Ratings History for Osiris Therapeutics (NASDAQ:OSIR)
Show:
DateFirmActionRatingPrice TargetDetails
3/16/2016Brean CapitalReiterated RatingSell$4.00View Rating Details
2/2/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details
(Data available from 9/26/2014 forward)

Earnings

Earnings History for Osiris Therapeutics (NASDAQ:OSIR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/7/2016        
11/6/2015Q315$0.06($0.02)$25.40 million$24.30 millionViewN/AView Earnings Details
8/5/2015Q215$0.06$0.03$23.60 million$23.70 millionViewN/AView Earnings Details
5/8/2015Q115$0.04$18.40 million$21.00 millionViewN/AView Earnings Details
3/5/2015Q414$0.05$0.03$18.53 million$19.50 millionViewN/AView Earnings Details
11/7/2014Q314($0.01)$0.02$14.80 million$17.20 millionViewN/AView Earnings Details
8/7/2014Q214$0.16($0.04)$11.00 million$13.30 millionViewN/AView Earnings Details
5/12/2014($0.08)($0.02)ViewN/AView Earnings Details
3/5/2014Q413$0.65$0.11$7.50 million$8.10 millionViewN/AView Earnings Details
11/1/2013Q313($0.10)($0.05)$6.70 million$6.88 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.09)($0.11)$4.35 million$5.29 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.09)($0.08)$3.53 million$4.06 millionViewN/AView Earnings Details
11/5/2012Q312($0.14)($0.09)$1.89 million$2.15 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Osiris Therapeutics (NASDAQ:OSIR)
Current Year EPS Consensus Estimate: $0.08 EPS
Next Year EPS Consensus Estimate: $0.07 EPS

Dividends

Dividend History for Osiris Therapeutics (NASDAQ:OSIR)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/17/2015special$0.209/14/20159/16/20159/30/2015
9/17/2015special$0.2010/14/201510/16/201510/30/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Osiris Therapeutics (NASDAQ:OSIR)
Insider Ownership Percentage: 44.60%
Institutional Ownership Percentage: 20.67%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/27/2014Matthew Paul NeumayerInsiderSell3,750$16.10$60,375.00View SEC Filing  
5/21/2014Philip Jacoby, Jr.CFOSell15,947$15.43$246,062.21View SEC Filing  
3/14/2014Michelle Leroux WilliamsInsiderSell61,934$14.09$872,650.06View SEC Filing  
11/25/2013Philip Jacoby, Jr.CFOSell18,372$15.99$293,768.28View SEC Filing  
11/15/2013Michelle Leroux WilliamsInsiderSell24,500$15.50$379,750.00View SEC Filing  
8/20/2013Matthew Paul NeumayerInsiderSell11,375$19.75$224,656.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Osiris Therapeutics (NASDAQ:OSIR)
DateHeadline
News IconKnee Cartilage Repair Market to Reach USD 2.4 Billion by 2020, Published by iHealthcareAnalyst, Inc. (NASDAQ:OSIR)
www.pr.com - September 24 at 11:01 AM
News IconRadiation Toxicity Radiation Sickness Acute Radiation Syndrome Market Expected to Expand at a Steady CAGR through 2026 (NASDAQ:OSIR)
www.emailwire.com - September 23 at 11:21 AM
News IconKnee Cartilage Repair Market to Reach USD 2.4 Billion by 2020, New Market Study by iHealthcareAnalyst, Inc. (NASDAQ:OSIR)
www.pr.com - September 22 at 11:28 AM
4-traders.com logoOsiris Therapeutics : Provides Update Regarding NASDAQ Listing Status (NASDAQ:OSIR)
www.4-traders.com - September 17 at 6:09 PM
globenewswire.com logoOsiris Provides Update Regarding NASDAQ Listing Status - GlobeNewswire (press release) (NASDAQ:OSIR)
globenewswire.com - September 17 at 11:02 AM
4-traders.com logoWayne Smith, Head of Canada's Statistics Agency, Quits (NASDAQ:OSIR)
www.4-traders.com - September 16 at 6:24 PM
publicnow.com logoOsiris Provides Update Regarding NASDAQ Listing Status (NASDAQ:OSIR)
www.publicnow.com - September 16 at 6:24 PM
News IconRadiation Toxicity Radiation Sickness Acute Radiation Syndrome Market Growth, Trends and Value Chain 2016-2026 by FMI (NASDAQ:OSIR)
reports.pr-inside.com - September 12 at 11:12 AM
live-pr.com logoNow Available: Osiris Therapeutics, Inc. (OSIR) - Financial and Strategic SWOT Analysis Review (NASDAQ:OSIR)
www.live-pr.com - August 24 at 6:25 PM
sbwire.com logoGlobal Stem Cells Market to Reach US $119.5 Bn by 2018, Rising Awareness About Therapeutic Benefits Boosts Popularity (NASDAQ:OSIR)
www.sbwire.com - August 20 at 10:45 AM
streetinsider.com logoOsiris Therapeutics (OSIR) Continues to Work to Complete ... - StreetInsider.com (NASDAQ:OSIR)
www.streetinsider.com - August 18 at 9:46 AM
biz.yahoo.com logoOSIRIS THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or S (NASDAQ:OSIR)
biz.yahoo.com - August 17 at 6:59 PM
publicnow.com logoOsiris Provides Update Regarding NASDAQ Listing Matters (NASDAQ:OSIR)
www.publicnow.com - August 17 at 6:59 PM
newsmaker.com.au logoBronchitis Treatment Market (Material, Production, Geography) 2016 Analysis and Forecast to 2022 (NASDAQ:OSIR)
www.newsmaker.com.au - August 12 at 6:48 PM
openpr.com logoStem Cells Being More Effective than Expected; Taking a look at the future (NASDAQ:OSIR)
www.openpr.com - August 11 at 9:57 AM
4-traders.com logoStocks, Oil Prices Start Week Firmly (NASDAQ:OSIR)
www.4-traders.com - August 8 at 11:21 AM
nasdaq.com logoOsiris Therapeutics, Inc. (Nasdaq: OSIR) to Ring The Nasdaq Stock Market Opening Bell - Nasdaq (NASDAQ:OSIR)
www.nasdaq.com - August 5 at 6:55 PM
streetinsider.com logoPre-Open Stock Movers 08/05: (RAX) (EGLT) (MRK) Higher; (HDP) (SWIR) (BMY) Lower (more...) (NASDAQ:OSIR)
www.streetinsider.com - August 5 at 9:46 AM
finance.yahoo.com logoGrafix® Manuscript Reporting Positive Outcomes of Multicenter Chronic Complex Wounds with Exposed Tendon … (NASDAQ:OSIR)
finance.yahoo.com - August 4 at 7:08 PM
finance.yahoo.com logo4:42 pm Osiris Therapeutics announces that the manuscript from its multicenter prospective post-market clinical trial using Grafix was accepted for publication in the International Wound Journal (NASDAQ:OSIR)
finance.yahoo.com - August 4 at 7:08 PM
publicnow.com logoGrafix® Manuscript Reporting Positive Outcomes of Multicenter Chronic Complex Wounds with Exposed Tendon and Bone Clinical Trial is Available Electronically in Peer-Reviewed Journal (NASDAQ:OSIR)
www.publicnow.com - August 4 at 7:08 PM
News IconLearn details of the global bronchitis treatment market 2015 industry trends, share, demand, volume growth, forecast 2022 (NASDAQ:OSIR)
www.whatech.com - July 28 at 9:54 AM
fiscalstandard.com logoBrokers Issue Average Price Target Of 17.75 On Osiris Therapeutics, Inc. (OSIR) - Fiscal Standard (NASDAQ:OSIR)
www.fiscalstandard.com - July 22 at 9:39 AM
News IconWere Analysts Bearish Osiris Therapeutics, Inc. (NASDAQ:OSIR) This Week? - Consumer Eagle (NASDAQ:OSIR)
www.consumereagle.com - July 19 at 7:41 AM
fiscalstandard.com logoOsiris Therapeutics, Inc. (OSIR) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:OSIR)
www.fiscalstandard.com - July 18 at 6:49 PM
News IconInstitutional Investors Are Crazy For Osiris Therapeutics Inc (NASDAQ:OSIR) - Consumer Eagle (NASDAQ:OSIR)
www.consumereagle.com - July 12 at 11:00 AM
News IconBronchitis Treatment – Global Market Outlook (2015-2022) (NASDAQ:OSIR)
empowerednews.net - July 11 at 6:40 PM
News IconWere Analysts Bearish Osiris Therapeutics, Inc. (NASDAQ:OSIR) This Week? - Press Telegraph (NASDAQ:OSIR)
presstelegraph.com - July 11 at 11:22 AM
News IconOsiris Therapeutics MD (NASDAQ:OSIR) Short Interest Decreased By 3.07% - Press Telegraph (NASDAQ:OSIR)
presstelegraph.com - July 7 at 6:44 PM
News IconBronchitis Treatment Market 2016 Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast to 2022 (NASDAQ:OSIR)
empowerednews.net - July 6 at 6:52 PM
einnews.com logo2016 Report on Bronchitis Treatment World Market Segmentation and Major Players Analysis 2022 (NASDAQ:OSIR)
world.einnews.com - July 6 at 6:52 PM
news.cmlviz.com logoOsiris Therapeutics, Inc. Stock Momentum Hits Extreme Weakness - CML News (NASDAQ:OSIR)
news.cmlviz.com - July 2 at 9:28 AM
News IconOsiris Therapeutics, Inc.'s Trend Down, Especially After Today's Weak Session - Engelwood Daily (NASDAQ:OSIR)
www.engelwooddaily.com - July 1 at 9:28 AM
fiscalstandard.com logoRecently Issued Stock Ratings For Osiris Therapeutics, Inc. (OSIR) - Fiscal Standard (NASDAQ:OSIR)
www.fiscalstandard.com - July 1 at 9:28 AM
4-traders.com logoOSIRIS THERAPEUTICS : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K/A) (NASDAQ:OSIR)
www.4-traders.com - June 29 at 6:36 PM
biz.yahoo.com logoOSIRIS THERAPEUTICS, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers, Financial Statements and E (NASDAQ:OSIR)
biz.yahoo.com - June 29 at 5:03 PM
News IconStock Volatility in Review: Osiris Therapeutics, Inc. (NASDAQ:OSIR) - Engelwood Daily (NASDAQ:OSIR)
www.engelwooddaily.com - June 27 at 6:38 PM
News IconOsiris Therapeutics MD (NASDAQ:OSIR) Short Interest Decreased By 3.07% - Engelwood Daily (NASDAQ:OSIR)
www.engelwooddaily.com - June 27 at 6:38 PM
News IconAre Analysts Bearish Osiris Therapeutics, Inc. (NASDAQ:OSIR) After Last Week? - Press Telegraph (NASDAQ:OSIR)
presstelegraph.com - June 27 at 10:52 AM
equities.com logoOsiris Therapeutics Inc. (OSIR) Jumps 5.77% on June 23 (NASDAQ:OSIR)
www.equities.com - June 25 at 6:09 PM
equities.com logoOsiris Therapeutics Inc. (OSIR) Jumps 5.77% on June 23 - Equities.com (NASDAQ:OSIR)
www.equities.com - June 25 at 10:24 AM
ftsenews.co.uk logoOsiris Therapeutics, Inc. (OSIR) Updated Price Targets - FTSE News (NASDAQ:OSIR)
www.ftsenews.co.uk - June 24 at 6:38 PM
equities.com logoOsiris Therapeutics Inc. (OSIR) Jumps 5.32% on June 20 (NASDAQ:OSIR)
www.equities.com - June 22 at 6:36 PM
equities.com logoOsiris Therapeutics Inc. (OSIR) Jumps 5.32% on June 20 - Equities.com (NASDAQ:OSIR)
www.equities.com - June 22 at 11:24 AM
kcregister.com logoWhy Making Dramatic Moves: Osiris Therapeutics, Inc. (NASDAQ:OSIR), BioScrip, Inc. (NASDAQ:BIOS), Yingli Green ... - KC Register (NASDAQ:OSIR)
www.kcregister.com - June 20 at 6:30 PM
bizjournals.com logoOsiris Therapeutics' stock falters amid executive shakeup, federal investigation (NASDAQ:OSIR)
www.bizjournals.com - June 16 at 10:54 AM
News IconInvestor News: Investigation of Osiris Therapeutics, Inc. (NASDAQ:OSIR) over possible Wrongdoing (NASDAQ:OSIR)
www.groundreport.com - June 13 at 6:15 PM
News IconInvestor News: Investigation of Osiris Therapeutics, Inc. (NASDAQ:OSIR) over possible Wrongdoing - GroundReport (NASDAQ:OSIR)
www.groundreport.com - June 13 at 9:38 AM
reuters.com logoBRIEF-Osiris Therapeutics says names David Dresner interim CEO - Reuters (NASDAQ:OSIR)
www.reuters.com - June 10 at 6:57 PM
feeds.reuters.com logoBRIEF-Osiris Therapeutics says names David Dresner interim CEO (NASDAQ:OSIR)
feeds.reuters.com - June 10 at 4:27 PM

Social

Osiris Therapeutics (NASDAQ:OSIR) Chart for Monday, September, 26, 2016


Last Updated on 9/26/2016 by MarketBeat.com Staff